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Background: Rabies is known to be lethal in human. Treatment with passive immunity for the rabies is effective
only when the patients have not shown the central nerve system (CNS) signs. The blood–brain barrier (BBB) is a
complex functional barrier that may compromise the therapeutic development in neurological diseases. The goal of
this study is to determine the change of BBB integrity and to assess the therapeutic possibility of enhancing BBB
permeability combined with passive immunity in the late stage of rabies virus infection.
Methods: The integrity of BBB permeability in rats was measured by quantitative ELISA for total IgG and albumin
levels in the cerebrospinal fluid (CSF) and by exogenously applying Evans blue as a tracer. Western blotting of
occludin and ZO-1, two tight junction proteins, was used to assess the molecular change of BBB structure.
The breakdown of BBB with hypertonic arabinose, recombinant tumor necrosis factor-alpha (rTNF-γ), and focused
ultrasound (FUS) were used to compare the extent of BBB disruption with rabies virus infection. Specific humoral
immunity was analyzed by immunofluorescent assay and rapid fluorescent focus inhibition test. Virus-neutralizing
monoclonal antibody (mAb) 8-10E was administered to rats with hypertonic breakdown of BBB as a passive
immunotherapy to prevent the death from rabies.
Results: The BBB permeability was altered on day 7 post-infection. Increased BBB permeability induced by rabies
virus infection was observed primarily in the cerebellum and spinal cord. Occludin was significantly decreased in
both the cerebral cortex and cerebellum. The rabies virus-specific antibody was not strongly elicited even in the
presence of clinical signs. Disruption of BBB had no direct association with the lethal outcome of rabies. Passive
immunotherapy with virus-neutralizing mAb 8-10E with the hypertonic breakdown of BBB prolonged the survival of
rabies virus-infected rats.
Conclusions: We demonstrated that the BBB permeability was altered in a rat model with rabies virus inoculation.
Delivery of neutralizing mAb to the infected site in brain combined with effective breakdown of BBB could be an
aggressive but feasible therapeutic mode in rabies when the CNS infection has been established.
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Rabies is a highly lethal disease caused by a neurotrophic
rabies virus. It has been estimated that about 55,000
persons died from rabies each year. In spite of the preva-
lence occurred primarily in Africa and Asia, the disease
exists globally [1]. Vaccines have been well developed for
the prophylaxis of the disease. When individuals are
infected with rabies, early post-exposure prophylaxis
(PEP) treatment may avoid death. Unfortunately, the
PEP treatment is deemed ineffective once the clinical
signs have appeared [2,3]. The mortality is almost 100%
once clinical signs were observed, although few cases
can survive successfully after the onset of symptoms
[4-8]. Because specialized blood–brain barrier (BBB) can
protect the CNS from a variety of injuries, it is reason-
able to assume that exclusion of immune cells or media-
tors from entering the CNS may lead to a lethal
outcome.
Recently, it had been reported that the BBB was more
permeable in mice infected with laboratory-attenuated
CVS-F3 than mice infected with silver-haired bat rabies
virus (SHBRV) [9,10]. The survival of SHBRV infected
mice was improved by enhancing the inflammatory re-
sponse and the delivery of immune effectors into the CNS
[9,10]. These studies suggested that the failure of increasing
BBB permeability may promote the disease development in
the pathogenic rabies virus-infected mice. Nevertheless,
increasing levels of total protein, blood cells count and
rabies virus-specific immunoglobulin in the CSF of patients
infected with pathogenic rabies virus have been reported
[7,8,11-13]. Neuroimaging showed abnormality of brain-
stem, thalamus, hypothalamus, hippocampus and basal
ganglia, and subcortical and deep white matter in some
patients diagnosed with rabies [12,14,15]. These clinical
findings implied the possibility of the BBB dysfunction in
human rabies. Whether alterations in the BBB permeability
could merely exist in attenuated but not pathogenic strain
or enhancement of the BBB permeability could prevent
disease progression after rabies virus infection is not
completely understood.
In the present study, we determined the BBB per-
meability and assessed the correlation between BBB
integrity and fatality in a rat model infected with
pathogenic rabies virus isolated from a dog-bite patient.
Further, we used passive immunotherapy with virus-
neutralizing mAb with BBB disruption to assess the prac-
ticability of this therapeutic strategy in the late stage of
rabies.
Methods
Animals, virus and mAb treatment
Eight- to ten-week-old male LEW/SsNNarl (LEW) rats
were purchased from National Laboratory Animal Center,
Taipei, Taiwan. They were infected via gastrocnemiusmuscle inoculation with 2 × 106 f.f.u. (focus-forming units)
rabies virus (Genotype 1; Accession AY431027, originally
from a rabid dog) in 100 μl phosphate buffer saline (PBS);
control animals received the same volume of PBS. The
animals were monitored twice daily and euthanized by
intraperitoneal injection of pentobarbital (150 mg/kg). In
passive immunity studies, the rats were injected with
rabies virus glycoprotein-specific, neutralizing mAb 8-10E
(IgG1κ, 1,800 IU/ml, generated at our laboratory) or with
normal saline alone at the indicated time. All procedures
were carried out according to the protocols approved
by the Institutional Animal Care and Use Committee
of Tzu-Chi University.
Serial collection of CSF from rats
The surgery was performed according to pervious
studies with minor modifications [16,17]. Briefly, rats
were anaesthetized with ketamine (80–100 mg/kg) and
xylazine (5–10 mg/kg) and immobilized on a stereotaxic
frame (model 51600, Stoelting, Wood Dale, IL, USA)
with self-made swivel mounts (15 cm). The skin overly-
ing the occipital bone was incised and the underlying tis-
sue was prepared as such that the atlanto-occipital
membrane in between the occipital bone and the upper
cervical vertebral was exposed. The cannula was made
of polyethylene tubing (PE-10). A hole was drilled
through the occipital bone, and the tube was allowed to
enter the cisterna magna. The tubing was occluded with
a blunt 27 G needle to prevent the escaping of the CSF.
The cannula was further attached to the skull using
dental cement (Lang Dental MFG, Chicago, IL, USA).
The CSF samples (25–50 μl) were collected and stored
at −80°C until analysis.
Quantitative ELISA
Immunoglobulin G (IgG) and albumin in the CSF and
serum were quantitated by sandwich ELISA using com-
mercial kits (Bethyl Laboratories, Mongomery, TX, USA).
Total IgG and albumin concentrations were measured in
duplicate.
Evans blue staining
BBB permeability was quantitatively evaluated by meas-
uring the amount of extravasated Evans blue (EB, Sigma,
St. Louis, MO, USA). EB (2%, 4 ml/kg body) was injected
intravenously and allowed to circulate for 1 h [18].
After washing with normal saline, the brains were removed,
weighted, and homogenized in 50% trichloroacetic
acid and centrifuged for 20 min at 13,000 rpm (5415R,
Eppendorf, Hamburg, Germany). The absorption of the
supernatant was measured at 620 nm with a spectro-
photometer (DU-7400, Beckman Coulter, CA, USA).
The concentration of EB dye was calculated using a
standard curve.
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Conventional Western blotting was used. Briefly, brain
samples were homogenized in ice-cold radioimmunopre-
cipitation (RIPA) buffer, supplemented with protease
inhibitor cocktail tablets (Roche Diagnostics GmbH,
Germany). The homogenates were centrifuged and pro-
tein concentrations of the supernatants were determined
using a Pierce protein assay kit (Pierce, Rockford, IL,
USA). Equal amounts of protein (80 μg) were loaded
onto 7.5% or 10% sodium dodecyl sulfate-polyacylamide
gel, transferred onto polyvinylidene difluoride mem-
branes (Millipore, Bedford, MA, USA). The membrane
was then blocked with 5% nonfat milk and incubated
with primary antibodies overnight at 4°C. The primary
antibodies and concentrations used were as follows:
rabbit polyclonal anti-occludin (Zymed Laboratories,
South San Francisco, CA, USA, 1:200), rabbit polyclonal
anti-ZO-1 (Zymed Laboratories, USA, 1:200), and mouse
monoclonal anti-β-actin (BD Biosciences, San Jose, CA,
USA, 1:5000). Following washing and incubation with
the secondary antibody (Chemicon, Temecula, CA, USA,
1:2000) for 60 min at room temperature, the membranes
were then probed with chemiluminescence reagents using
a commercially available kit (ECL Plus Western blotting
detection system, Amersham Biosciences, Little Chalfont,
Buckinghamshire, UK) to visualize the signals, followed by
exposure to X-ray films (Kodak, Rochester, NY, USA). In-
tensities of the band were quantified with a densitometric
analysis system (GS-800 Calibrated Densitometer, Bio-
Rad, Hercules, CA, USA), and calculated as the optical
density x area of band.
Disruption of BBB permeability
Three methods were use to disrupt the BBB permeabil-
ity. Hyperosmotic solution and TNF-α were performed
as described previously [19-21]. Briefly, rats were
anesthetized with ketamine (80–100 mg/kg) and xylazine
(5–10 mg/kg), and infused via carotid artery with 1.6 M
arabinose (0.12 ml/sec, constant for 30 sec) or 106 IU
human recombinant TNF-α protein (Peprotech Inc,
Rocky Hill, NJ, USA). FUS treatment was described pre-
viously [22,23]. SonoVueW SF6-coated ultrasound micro-
bubbles (2–5 mm mean diameter, 1.5 mg/kg; Bracco
Diagnostics Inc., Princeton, NJ, USA) were administered
intravenously by continuous injection with 0.2 ml saline
solution containing 0.1 ml heparin by a micropump
(0.6 ml/min). Moderate ultrasound power (4.3 W, equiva-
lent to a pressure of 0.4 MPa) was delivered to the brain
with the center of the focal zone positioned at a penetra-
tion depth of 2–3 mm. In order to increase the BBB
permeability of entire half brain, multiple exposures were
carried out to completely cover the hemisphere. Animals
typically underwent 3 sonications, with the spacing be-
tween individual adjacent focal positions set to 3 mm. Ineach sonication, burst mode ultrasound was delivered with
the following parameters: burst length=10 ms, pulse re-
petitive frequency=2 Hz, and sonication duration=1 min.
Measurement of serum and CSF antibody titers
Levels of rabies virus-specific total IgG from rats
infected with rabies virus as well as uninfected control
groups were measured by indirect immunofluorescent
assay (IFA). The titer was defined as the reciprocal of
the highest dilution factor of test samples in which 50% or
more of the fields examined contained specifically fluores-
cing cells. Virus-neutralizing antibody (VNA) titers were
determined by the rapid fluorescent focus inhibition test
(RFFIT) as previously described [24,25]. The VNA titer
was determined as the last dilution of serum that was
capable of reducing the number of FFU by 50%.
Passive immunotherapy with BBB opening
Experiments were divided into two parts: (1) for the pas-
sive immunotherapy alone, the rabies virus-infected rats
were intraperitoneally administrated 10 mg mAb 8-10E,
and (2) for the passive immunotherapy combined with
BBB opening (BBBO), mAb 8-10E was administered
6 hrs before BBB disruption. The studies were carried
out on day 7 and day 9 post-infection (p.i.). The rats
were continually observed to day 40 p.i. and then eutha-
nized for analysis.
Reverse transcription-polymerase chain reaction (RT-PCR)
analysis
Total RNA was extracted from the cerebral cortex, cere-
bellum, and spinal cord of rabies virus infected and
control rats using the RNeasy Mini kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
The nucleoprotein (N) gene of rabies virus was amplified
by one-step RT-PCR. The nucleotide sequences of the
primers used for PCR are forward primer, 5'- CTA
CAATGGATGCCGAC-3' and reverse primer, 5'-TCA
TAACGGAGAGATCGCCAC-3'. RT-PCR was per-
formed with 4 μl of RNA (0.2-0.4 μg) and the OneStep
RT-PCR kit (Qiagen, Germany) according to the manu-
facture’s instructions. Each reaction mixture was incu-
bated at 50°C for 30 min, followed by 40 cycles at 94°C
for 30 sec, 55°C for 30 sec, 72°C for 1 min, and 72°C
for 10 min. Equal amounts of amplified PCR products
were electrophoresed in 1.5% agarose gels containing
ethidium bromide. The bands were visualized under
UV light and photographed.
Statistical analysis
All data were expressed as mean ± SEM. One-way
ANOVA was used to compare means between experi-
mental groups. Student’s t-test was used to determine
the significance between groups. The survival rate was
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statistics were used to test the difference between
groups. The GraphPad Prism statistical package, version
5.0c (GraphPad Software, Inc., San Diego, CA, USA) was
used for comparison. Differences were considered statis-
tically significant at p < 0.05.
Results
Rabies viral antigens were detected in the CNS of LEW
rats after challenge
Clinical signs of rabies infection appeared on day 9–10
p.i.. Unsteady gait and hunched back were observed
in the beginning, swimming movement, slow motion,
and limbs paralysis in the late stage. Rats died from
the infection within 2 to 4 days once the neural signs
were observed. The viral genome was detected by
IFA, RT-PCR and immunohistochemistry on day 5 p.i.
in the brain and spread out within the next 2 days
(data not shown).
BBB permeability was disrupted after rabies virus
challenge
To determine the possible alteration of BBB permeabil-
ity, the CSF were serially sampled and analyzed. The
status of the BBB permeability was monitored post-
infection every single day by quantifying the albumin
and total IgG in the CSF using quantitative ELISA. The
results showed that the albumin and total IgG levels
were elevated significantly on day 7 and continuallyFigure 1 BBB permeability was altered in the CSF of rats infected wit
albumin and (B) total IgG from the CSF after rabies virus infection and exp
differences in permeability was calculated using Student’s t-test and are de
presented in (C) for albumin and (D) for IgG. Each dot represented one indelevated to day 12 p.i. (Figure 1A, B). The time course of
the changes of the CSF to serum ratios of albumin and
total IgG in rabies virus-infected rats is shown in
Figure 1C and D. There were about 7- and 10-fold
increase in albumin and total IgG, respectively, in the
CSF on day 12 p.i. when compared to uninfected rats.
The time course of the increase in BBB permeability
paralleled that of animal illness.
BBB permeability alterations were observed in the
cerebellum and spinal cord with EB staining
To evaluate the regional differences in BBB permeability
alterations, we measured the extravasations of EB from
the circulation into the CNS tissues on day 10 to 11 p.i..
Staining of Evans blue was found mainly in the cerebel-
lum and spinal cord. There were about 11- and 20-fold
increase in the cerebellum and spinal cord, respectively,
compared to control rats (Figure 2). In contrast,
relatively mild cerebral cortical BBB breakdown was
observed as revealed by a no significant difference in EB
staining. The results indicated that the integrity of the
BBB was changed after rabies virus infection, and the
major alteration were observed in the cerebellum and
spinal cord.
Tight junction protein occludin was degraded after rabies
virus infection
To investigate whether BBB breakdown in the brain is asso-
ciated with the changes of endothelial tight junctionh rabies virus. BBB permeability was assessed by measuring (A)
ressed as the concentration (μg/ml) (n = 8). Statistical significance of
noted by the symbol *p< 0.05. The CSF to serum ratios were
ividual rat.
Figure 2 Localization of BBB permeability changes in the brain
of rabies virus-infected rats. Brains were removed from Evans
blue-treated rats either in the control or rabies virus-infected animals
on day 10 to 11 p.i.. BBB permeability was assessed by measuring
the EB content which was determined by a standard curve.
Compared with controls (n = 4), rabies virus-infected rats (n = 8)
showed a significant increased in the amount of EB (*p< 0.05).
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cerebellum were immunoblotted. Figure 3A shows that the
expression levels of occludin in the cerebral cortex and
cerebellum were decreased after rabies virus infection.
Occludin levels in the cerebral cortex and cerebellum were
decreased by 37±9% and 41±9%, respectively (Figure 3B).Figure 3 Expression of tight junction protein, occludin, was decrease
tight junction proteins, occludin and ZO-1, were shown in (A) the cerebral
occludin and (C) ZO-1 expression were determined by densitometric analy
corresponding β-actin bands. Results are expressed as mean± SEM. *p< 0.0Conversely, protein levels of ZO-1 were not significantly
changed in the cerebral cortex and cerebellum (Figure 3C).
These data indicated that rabies virus infection can disrupt
BBB permeability through down-regulating the expression
of occludin but not ZO-1 in the brain.
The extent of BBB opening via hypertonic solution, TNF-α
or FUS treatment
To measure the extent of BBB opening after hypertonic
arabinose, TNF-α or FUS treatment, the albumin and total
IgG levels of the CSF were continually analyzed using
quantitative ELISA. In hypertonic breakdown with arabin-
ose, the albumin and total IgG levels were elevated within
0.5 hr and reached the peak at 2 hr. The highest concen-
tration was 1062.38 ± 146.10 μg/ml for the albumin and
52.59 ± 5.22 μg/ml for the total IgG. After 4 and 12 hr, the
albumin and total IgG returned gradually to the control
levels (Figure 4A, B). Following rTNF-α infusion, the BBB
permeability was significantly decreased only at 2 hr; no
significant effect was observed at other time points
(Figure 4C, D). After FUS treatment, the BBB permeability
was increased significantly at 1 hr and returned to control
levels at 6 hr. The concentration of albumin was
324.40± 15.61 μg/ml and total IgG was 17.11 ± 2.17 μg/ml
at 1 hr post treatment (Figure 4E, F).
BBB opening was not the primary determinant for
lethality of rabies virus infection
Our study showed that BBB opening (BBBO) was signifi-
cant elevated following hypertonic arabinose infusion ind in the brains of rabies-infected rats. Western blotting analyses of
cortex and cerebellum. Relative levels of tight junction protein (B)
sis. All samples analyzed (n = 4) were normalized to the intensity of
5, significantly different from the control rats.
Figure 4 Alteration of BBB permeability was compared in three methods. BBB permeability was assessed by measuring the albumin (A, C,
E) and total IgG (B, D, F) contents from the CSF after hypertonic arabinose (n = 8), rTNF-α (n = 5) and FUS (n = 5) treatment. The data were
expressed as the concentration (μg/ml). Statistical significance of differences in BBB permeability was calculated using Student’s t-test and are
denoted by the symbol *p< 0.05.
Figure 5 Survival percentage of rabies virus-infected rats
infused with or without BBBO. Groups of rats (n = 7) after rabies
virus (RV) infection were infused with or without hyperosmotic
arabinose to disrupt BBB on day 7 and 9 p.i. and assessed the
morbidity and mortality. BBBO was performed as described in the
Methods. Comparison between RV alone and RV plus BBBO showed
no significant difference between each groups (p> 0.05).
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tonic arabinose was performed on day 7 and 9 p.i.. The
rats treated with or without hyperosmotic solution all
died after rabies virus infection. Figure 5 showed that
the percentage of survival was not different between the
control (infection only) and the experimental groups
(infection + BBBO). It could be postulated that the
enhancement of BBB permeability was not the primary
determinant for lethality of rabies virus infection.
Specific anti-rabies virus antibody of the CNS tissue was
not detected in the CSF and was lower in peripheral sera
To estimate the humoral immunity of the rabies virus-
infected rats, we measured the rabies virus-specific IgG
and virus-neutralizing antibody (VNA) titer in the serum
and CSF using IFA and RFFIT. The IFA results showed
that the rabies virus-specific antibody was detected in
the sera, but the mean of dilution factor was lower than
1:256 on day 11 p.i.. In the CSF, the antibody level was
very low and the mean of dilution factor was less than
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the rabies virus-neutralizing titer was slightly increased
in the sera and was limited in the CSF (Figure 6B). Con-
sequently, the virus-specific antibody and immune re-
sponse were insufficient to protect the animals from
rabies virus infection.
Rabid rats survived longer when the virus-neutralizing
mAb entered the CNS
To examine further if the survival rate may be increased
when sufficient mAb crosses into the CNS, 10 mg rabies
virus neutralizing mAb 8-10E (9000 IU) was adminis-
tered to rabies virus-infected rats with or without BBBO
(Figure 7A). Administration of mAb 8-10E alone on day
7 p.i. increased the survival rate from 0 to 33.3% and up
to 42.9% when mAb 8-10E was combined with BBBO.
Treatment with mAb alone on day 9 p.i. also increased
the survival percentage to 28.6%. However, there was no
further improvement in rats treated with mAb 8-10E
combined with BBBO on day 9 p.i.. Instead, all the rats
expired within 15 days p.i. (Figure 7B). Approximately
half of the rats which were administered mAb 8-10E
with BBBO on day 7 p.i. survived at least for forty days.
There was a significant difference between 8-10E alone
(on day 7 p.i.), 8-10E ±BBBO (on day 7 p.i.), and 8-10E
alone (on day 9 p.i.) vs. control in the survival analysis. To
clarify the CNS infectivity after BBBO and mAb treat-
ment, rabies viral genome was amplified by RT-PCR. The
viral genome in cerebrum, cerebellum and spinal cord was
not detectable from the control and those groups of rats
survived to day 40 p.i. (Figure 7C). In contrast, viral
genome was found in the brain tissues from rats died of
severe neurological signs (Figure 7C).
Discussion
The BBB is a functional and structural component of the
CNS vasculature that serves important protective func-
tions for the CNS. Many clinical symptoms, immune
responses, pathological changes and disease outcome inFigure 6 Rabies virus-specific antibody productions were slightly elic
antibody (VNA) production in the sera and CSF of rabies virus-infected rats (n
presented as the geometric mean±SEM of the last dilution of serum and CSFneurodegeneration or infectious diseases have been asso-
ciated with the BBB permeability [26]. Alterations of BBB
permeability have been reported after pathogenic rabies
virus infection in human. Elevation of immune cells and
leakage of serum components from circulation could be
detected in some patients suffered from rabies [7,8,11-13].
In the present study, we demonstrated that the BBB perme-
ability was altered after pathogenic rabies virus infection in
a rat model, which was not consistent with previous studies
in mice [9,10]. It could be speculated that in some animals,
like laboratory rats, the BBB integrity indeed may be chan-
ged after pathogenic rabies virus infection.
Serial sampling of CSF from rabies virus-infected rats
presents a dynamic change of the BBB permeability. We
found that serum proteins, albumin and total IgG, were
elevated on day 7 p.i. and increased further afterwards.
Our preliminary study showed that the rabies virus
could retrogradely replicate in the brain tissues on day 5
p.i. and clinical symptoms were observed on day 9 p.i.. We
postulate that the initiation of the BBB opening was be-
hind the replication of rabies virus in the CNS but prior to
the appearance of clinical signs. Further, we also demon-
strated that the disruption of BBB could allow macromol-
ecular markers, e.g., albumin and IgG, to leak into the
CNS. This result was substantiated by the Evans blue
staining. The greater permeability was seen in the spinal
cord and cerebellum compared with the cerebral cortex
on day 10 to 11 p.i.. This similar regional difference was
reported also in the attenuated CVS-F3 study in mice
[27]. Together, these observations indicate that pathogenic
rabies virus infection in the nervous tissues could allow
the serum proteins passing through the BBB and loss
of BBB integrity was more extensive to molecules
from 66 to 150 kDa in the cerebellum and spinal
cord than the cerebral cortex in rats.
Tight junction proteins, the essential components of
the BBB, are the primary barrier to maintain the brain
homeostasis [26]. Alterations of tight junction protein
expression and discontinuous cell junctions have beenited after infection. Kinetics of (A) specific IgG and (B) virus-neutralizing
=8) were assessed by IFA and RFFIT, respectively. Levels of antibodies are
.
Figure 7 Survival of rabies virus-infected rats treated with passive
immunotherapy alone or in combination with BBBO. (A) Diagram
of treatment schedule: on day 7 and 9 p.i., group 1 animals received
mAb 8-10E alone (n = 7) and group 2 animals received mAb 8-
10E + BBBO (n= 8), (B) Survival of rats following infection with four
different treatment: (1) 8-10E alone on day 7 p.i., (2) 8-10E + BBBO on
day 7 p.i., (3) 8-10E alone on day 9 p.i., and (4) 8-10E + BBBO on day
9 p.i.. Rats were monitored for morbidity and mortality for 40 days.
8-10E: indicated that rats was injected with virus-neutralizing mAb
8-10E. BBBO: indicated that the BBB permeability was enhanced with
hypertonic arabinose infusion. Statistical significance of differences in
survival rats was denoted by the symbol *p<0.05. (C) Detection of
viral RNA in the brain tissues infected with rabies virus. Viral
nucleoprotein mRNA expression was detected in the cerebrum,
cerebellum and spinal cord of rats died of BBBO and mAb
8-10E + BBBO treatment on day 14 p.i. (numbered 1, 2, 3, 4). The size
of the amplified fragment was estimated to be 777 bp. No viral
genome was detected in the brain tissues and spinal cord of rats
survived for 40 day p.i. (numbered 5, 6, 7, 8). The lane marked “P” is
the positive control taken from a cultured virus suspension.
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cerebral infarction, multiple sclerosis, viral infection,
and neurodegeneration [28-31]. Our analysis of major
tight junction proteins revealed a unique susceptibility
of occludin but not ZO-1 after rabies virus infection
in both the cerebral cortex and cerebellum. Decreased
expression of occludin leads to increased BBB perme-
ability [32-34]. These findings are consistent with ourpresent study demonstrating that the decreased expres-
sion of occludin is accompanied by BBB hyperpermeabil-
ity in rabies virus-infected rats. Our findings indicate that
rabies virus infection could trigger the BBB disruption.
Nevertheless, other tight junction proteins, such as clau-
dins and junctional adhesion molecule also contribute
structurally to the formation of BBB [34,35]. These
proteins may participate in the rabies mediated changes of
BBB permeability. However, more investigations are
needed to clarify its role.
According to the results of quantitative ELISA and Evans
blue study, the rabies virus infection induced BBB leakage
of macromolecules was restricted to the cerebellum and
spinal cord. We compared hypertonic arabinose, TNF-α,
and FUS to find out which method could enhance greater
BBB disruption and allow more macromolecules, such as
IgG, to enter the brain. Intracarotid infusion of a hypertonic
solution caused a transient and reversible shrinkage of the
endothelial cells and opening of the endothelial tight junc-
tions and increasing the delivery of antineoplastic agents,
neutralizing antibodies, mAbs, nanoparticles and viral
vectors into the CNS [36-40]. Intracarotid and intracerebral
rTNF-α administration could result in BBB opening for
different tracers, such as sodium fluorescein, horseradish
peroxidase, albumin, and endogenous IgG [41,42]. FUS
combined with microbubbles has been shown to be capable
of BBB opening, and it improved the delivery of anti-tumor
compounds and antibodies into the brain [43,44]. We
found that FUS and hypertonic arabinose could effectively
open the BBB and raise the concentrations of macromole-
cules detected in the CSF. In contrast, exogenous rTNF-α
injection did not induce BBB leakage for large molecules
and even inhibited BBB permeability. However, we could
not exclude the possibility that small molecules may pass
through the BBB.
Although BBB permeability was changed after rabies
virus infection, the mortality was not altered. This is
mainly resulted from the insufficient titer of neutralization
antibody for rabies virus, which was substantiated by the
finding of lower levels of virus-specific and neutralizating
antibody in the sera and the CSF. This result is similar to
human naturally infected with rabies virus. They do not
receive PEP and generally do not mount a strong immune
response to rabies relatively late in the disease [7,45].
VNA can be detected in the sera and CSF, but the titers
are usually relatively low [7,12]. Insufficient antibodies
could not provide appropriate protection in peripheral
and central nervous tissues. It is surmised that enhancing
the BBB permeability without a concomitant increase of
antibodies in the CNS would be futile to protect against
the lethality after rabies virus infection. In this regard, it is
important to note that delivery of high levels of virus-
neutralizing mAb to the CNS tissues should diminish
lethality and clear rabies virus.
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antibodies accompanied with the enhancement of BBB
permeability can raise the survival more than the adminis-
tration of monoclonal antibodies alone [46,47]. In our
study, PEP treatment using virus-neutralizing mAb 8-10E
combined with BBB disruption elevated the survival in
LEW rats inoculated with rabies virus on day 7 p.i., how-
ever; the effect was diminished on day 9 p.i.. One possible
explanation may be that the adverse effects of osmotic
infusion, such as seizures, reinforce damage to the brain
already exhibiting neuronal dysfunction [48]. It is surpris-
ing to note that neutralizing mAb 8-10E treatment alone
increased the survival rate by 33.3% and 28.6%. respect-
ively, on day 7 and 9 p.i. We hypothesize that administra-
tion of sufficient neutralizing mAbs into the CNS could
rescue the rats from rabies-induced lethality and early
treatment with mAb also increase survival rate.
Until now, besides the success of the Wisconsin’s
patient treated with the Milwaukee Protocol, several
others have employed similar treatment regimens with
minimal beneficial outcomes [6,49-51]. Although a frac-
tion of rabies virus-infected rats could be saved with
passive neutralizing mAb treatment, whether greater
improvement could be achieved with immune therapy
needs more studies. In future development, a passively
administrated mAb or such a humanized mAb com-
bined with effective and global BBB breakdown may pro-
vide an alternative therapy for rescuing patients who
have been diagnosed with rabies.
Conclusions
The present study revealed that BBB permeability was
altered after pathogenic rabies virus infection in rats.
Sufficient virus-neutralizing antibody plays a major role
in determining the survival from rabies virus infection.
Our study indicates that enhancing BBB opening com-
bined with delivering sufficient virus-neutralizing mAb
to the brain may provide an effective treatment when
the CNS infection has been established.
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